FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

ICH Drug Submission Quality Information Guidance

[ Price : $8.95]

FDA publishes for review and comment the International Council for Harmonization M4Q(R2) guidance establishing the location and st...

4 CGMP Issues at Integrity Partners Facility

[ Price : $8.95]

FDA warns Integrity Partners St. Louis, MO-based Chemisphere drug manufacturing facility about CGMP issues in its production of fi...

Valneva Withdraws BLA for Chikungunya Vaccine

[ Price : $8.95]

Valneva says it has voluntarily withdrawn its BLA for Ixchiq, the companys chikungunya vaccine, based on FDA safety-related restri...

Celcuity NDA Gets Priority Review for Breast Cancer

[ Price : $8.95]

FDA accepts for priority review a Celcuity NDA for gedatolisib in patients with hormone receptorpositive, HER2-negative, PIK3CA wi...

Objectionable Conditions in Prodrome Sciences BIMO Inspection

[ Price : $8.95]

FDA warns Temecula, CA-based Prodrome Sciences USA about violations in its conduct of a clinical trial without submitting an IND.

Guide on Endpoints for Multiple Myeloma Accelerated Approval

[ Price : $8.95]

FDA posts a draft guidance outlining how drug developers can use minimal residual disease and complete response as primary endpoin...

Novo Nordisk Supplements Semaglutide Petition

[ Price : $8.95]

Novo Nordisk submits to FDA additional studies and analyses it says support its petition asking the agency to act against compound...

Qualgen FDA 483 Cites Quality Issues

[ Price : $8.95]

FDA inspectors cite Oklahoma-based outsourcing facility Qualgen for a wide range of manufacturing and quality control failures dur...

High Court Agrees to Hear Skinny Label Dispute

[ Price : $8.95]

The U.S. Supreme Court agrees to hear a patent-infringement dispute between generic drugmaker Hikma Pharmaceuticals USA, Inc. and ...

Pazdur, Others Concerned About Voucher Program Integrity

[ Price : $8.95]

Former FDA oncology drug leader Richard Pazdur says concerns surrounding a controversial fast-track drug review initiative under c...